Vanguard Capital Management
RNAZ icon

Vanguard Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

Vanguard Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.6K Hold
6,545
– – ﹤0.01% 3953
2026
Q1 		$56.4K Buy
+6,545
New +$61.1K ﹤0.01% 3907

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Capital Management's RNAZ Position: Q2 2026 in Review

Vanguard Capital Management held its TransCode Therapeutics (RNAZ) position steady in Q2 2026 at 6,545 shares worth $40.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3953.

Vanguard Capital Management first reported a position in RNAZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $56.4K in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Vanguard Capital Management held 6,545 shares of TransCode Therapeutics worth $40.6K as of Q2 2026.
  • Vanguard Capital Management left its TransCode Therapeutics share count unchanged in Q2 2026.
  • TransCode Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3953 holding.
  • Vanguard Capital Management first reported a position in TransCode Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's TransCode Therapeutics position peaked at $56.4K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.